Bitwise’s acquisition of Chorus One expands the company’s staking capabilities to more than 30 blockchains, including Solana, Hyperliquid, Monad, Avalanche and Sui. Crypto asset manager Bitwise has ...

Bitwise buys Chorus One, scaling staking across 30+ PoS networks fast. Chorus One deal adds 50 engineers to supercharge Bitwise staking ops. Bitwise Onchain Solutions grows bigger, targeting ...

Bitwise Asset Management wants to offer a prediction markets for the next U.S. presidential election through exchange-traded funds (ETFs). Under "Prediction Shares" branding, the San Francisco-based ...

Bitwise has filed for a prediction market ETF targeting major U.S. elections. The move is indicative of increasing institutional interest in political event-based contracts. Industry observers are ...

Crypto asset manager Bitwise launched seven model portfolios focused on digital assets. The portfolios, tailored to serve different investor risk preferences, will allow financial advisors to give ...

The Chorus One acquisition strengthens Bitwise’s control over staking as institutional investors increasingly prioritize yield. Crypto fund manager Bitwise recently acquired institutional staking ...

Over the past 12 months, the Bitwise Crypto Industry Innovators ETF has outperformed Bitcoin. Rather than holding just a single cryptocurrency, the Bitwise ETF holds a diversified portfolio of 29 ...

Bitwise is collaborating with Morpho to launch non-custodial on-chain vaults. The company’s portfolio manager, Jonathan Man, will lead the new alliance. In line with its crypto push, it recently ...

Bitwise Asset Management, a global crypto asset manager, has launched a new onchain investor offering through non-custodial vault strategies on Morpho, an onchain lending network. Finance is moving ...

The first vault strategy targets 6% annual percentage yield via over-collateralized lending pools, managed by Bitwise. Digital asset management firm Bitwise has teamed up with decentralized finance ...

FDA Fast Track designation has been granted to CTx001 for Geographic Atrophy secondary to Age-related Macular Degeneration CTx001 is an investigational AAV-based gene therapy designed to modulate ...